Country: Canada
Language: English
Source: Health Canada
OLODATEROL (OLODATEROL HYDROCHLORIDE)
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
R03AC19
OLODATEROL
2.5MCG
SOLUTION
OLODATEROL (OLODATEROL HYDROCHLORIDE) 2.5MCG
INHALATION
100
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0154370001; AHFS:
CANCELLED PRE MARKET
2021-11-10
_ _ _Striverdi_ _®_ _ Respimat_ _®_ _ Product Monograph _ _ _ _Page 1 of 41_ PRODUCT MONOGRAPH PR STRIVERDI ® RESPIMAT ® Olodaterol Hydrochloride Inhalation Solution, 2.5 mcg Olodaterol/Actuation (as olodaterol hydrochloride) STRIVERDI ® RESPIMAT ® cartridge for use only with the STRIVERDI ® RESPIMAT ® inhaler Long-acting beta 2 -agonist Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 Date of Preparation: May 13, 2019 www.boehringer-ingelheim.ca Submission Control No: 224290 Striverdi ® and Respimat ® are registered trademarks and used under license from Boehringer Ingelheim International GmbH BICL #: 0270-04 _ _ _Striverdi_ _®_ _ Respimat_ _®_ _ Product Monograph _ _ _ _Page 2 of 41_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................12 OVERDOSAGE ................................................................................................................12 ACTION AND CLINICAL PHARMACOLOGY ............................................................13 STORAGE AND STABILITY ..........................................................................................18 SPECIAL HANDLING INSTRUCTIONS ................................. Read the complete document